-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $80

Benzinga·08/06/2026 11:26:49
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $67 to $80.